Literature DB >> 8580066

Staging of Burkitt's lymphoma and response to treatment monitored by PET scanning.

S F Barrington1, R Carr.   

Abstract

Positron emission tomography (PET) is an imaging technique using biological tracers (18-fluorine fluorodeoxyglucose (FDG)), whose uptake into tumour cells is increased. Previous studies carried out in patients with lymphoma have shown that PET is an accurate method of staging disease and that a high pre-treatment FDG uptake that is abolished by the end of chemotherapy is associated with a good clinical response. This case report demonstrates that clinical PET scanning can be especially useful in staging patients with lymphoma in whom there is extensive extranodal and marrow involvement, and that PET can follow changes in tumour viability over a very short time span.

Entities:  

Mesh:

Year:  1995        PMID: 8580066     DOI: 10.1016/s0936-6555(05)80549-7

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  3 in total

1.  Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?

Authors:  Pierre Y Salaun; Thomas Gastinne; Caroline Bodet-Milin; Loïc Campion; Pierre Cambefort; Anne Moreau; Steven Le Gouill; Christian Berthou; Philippe Moreau; Françoise Kraeber-Bodéré
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-05       Impact factor: 9.236

Review 2.  FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.

Authors:  Sally F Barrington; Regine Kluge
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

3.  Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt's lymphoma.

Authors:  Wen-Xiao Wei; Jia-Jia Huang; Wen-Yu Li; Xu Zhang; Yi Xia; Wen-Qi Jiang; Wei Fan; Zhi-Ming Li
Journal:  Chin J Cancer       Date:  2015-12-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.